Ganetespib: Phase II discontinued
An open-label, U.S. Phase II trial in 26 evaluable patients with esophagogastric cancer who progressed on <=2 lines of systemic therapy was discontinued after 200 mg/m 2 IV ganetespib on days 1, 8 and 15 of a 28-day cycle produced "insufficient evidence of single agent activity." Specifically, ganetespib led to an ORR of 4%, with 1 complete response. Time to progression was 48 days and overall survival (OS) was 83 days. Additionally, 2 of 6 patients with HER2-positive disease achieved 12% and 19% tumor reductions from baseline, respectively. The most common grade 3/4 adverse events were leucopenia, fatigue, diarrhea and elevated anaplastic lymphoma kinase (ALK) protein levels. The trial was sponsored by Massachusetts General Hospital. Data will be presented at the American Society of Clinical Oncology meeting in Chicago in June. ...